Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 May 29;8(8):1687-1691.
doi: 10.1016/j.ekir.2023.05.017. eCollection 2023 Aug.

Avacopan in Patients With Rapidly Progressive Glomerulonephritis Requiring Dialysis

Affiliations
Case Reports

Avacopan in Patients With Rapidly Progressive Glomerulonephritis Requiring Dialysis

Frank B Cortazar et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) A representative glomerulus from case #1 exhibits segmental GBM glomerular basement membrane rupture (arrow) associated with fibrin extravasation into the urinary space and segmental cellular crescent formation. Marinating neutrophils, some of which are undergoing karyorrhexsis, are admixed with fibrin in several capillary loops (×200, Jones methenamine silver; JMS). (b) A representative glomerulus from case #2 displays a circumferential cellular crescent compressing the underlying glomerular tuft. There is also focal disruption of Bowman’s capsule (×200, JMS). (c) A segmental cellular crescent (arrow) from case #3’s kidney biopsy. The uninvolved portions of the glomerular tuft are normocellular with patent capillary lumina, typical of ANCA-mediated glomerulonephritis (×200, JMS). (d) Immunofluorescence staining for case #3 revealed intense (3+) linear staining of glomerular basement membranes for IgG, typical of anti- glomerular basement membrane- GBM disease. Foci of glomerular basement membrane GBM rupture were apparent (arrow). This patient was also found to have proteinase-3 PR3-ANCA seropositivity (×200, immunofluorescence microscopy).

References

    1. Zonozi R., Niles J.L., Cortazar F.B. Renal involvement in antineutrophil cytoplasmic antibody-associated vasculitis. Rheum Dis Clin North Am. 2018;44:525–543. doi: 10.1016/j.rdc.2018.06.001. - DOI - PubMed
    1. Flossmann O., Berden A., de Groot K., et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:488–494. doi: 10.1136/ard.2010.137778. - DOI - PubMed
    1. Lee T., Gasim A., Derebail V.K., et al. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol. 2014;9:905–913. doi: 10.2215/CJN.08290813. - DOI - PMC - PubMed
    1. Stone J.H., Merkel P.A., Spiera R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–232. doi: 10.1056/NEJMoa0909905. - DOI - PMC - PubMed
    1. Jayne D.R.W., Merkel P.A., Schall T.J., Bekker P., ADVOCATE Study Group Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599–609. doi: 10.1056/NEJMoa2023386. - DOI - PubMed

Publication types

LinkOut - more resources